Amber M. Pang Parra is a pharmaceuticals attorney. She served as attorney with the state and federal judiciaries before moving to private practice, where she focuses on pharmaceutical and medical device litigation.

Supreme Court Permits Removal under CAFA Without Proof of Amount in Controversy

The Supreme Court overruled the Tenth Circuit in finding that a petition for removal to the federal courts under  the Class Action Fairness Act of 2005  (CAFA), 28 U.S.C. Sec. 1332(d)(A)-(C), was sufficient. The Court found that under CAFA, which gives federal courts jurisdiction over class actions if the amount in controversy exceeds $5 million,

Walgreens Held Liable in Privacy Suit

Health care privacy law, as we’ve noted here, is an area of law that continues to grow at a precipitous rate.  HIPAA and health care privacy protections may  intersect with employment law issues, underscoring the weight of responsibility for all keepers and handlers of private medical information — and the people and companies that may

Boston Scientific Pelvic Mesh Developments

Pelvic mesh litigation now comprises over 60,000 cases in the federal MDL, proceeding in the Southern District of West Virginia, and notable developments in the MDL and in cases proceeding in state and federal courts continue as cases prepare for bellwether trials. Judge Goodwin issued a fascinating opinion on the application of the learned intermediary

Cook Medical IVC MDL Cases Transfered to Southern District of Indiana

Plaintiffs in 12 of 27 pending cases against Cook Medical successfully moved the Judicial Panel on Multi District Litigation (“JPMDL”) for centralization of their cases into an MDL.  These cases were centralized into an MDL,  In re Cook Medical, Inc., IVC Filters Marketing, Sales Practices, and Products Liability Location, MDL No. 2570, and were transferred

Mylan and EpiPens in the News

Mylan Pharmaceuticals is splashed across news sites as it announces a partnership with Disney theme parks, to make park users more aware of stations set up for use of EpiPen epinephrine autoinjectors, for patrons experiencing severe allergic reactions. Mylan also announced that it was expanding a program to provide the autoinjector pens, free of charge,

HIPAA, Tort Reform, and State Law Remedies for Violations

The demand for privacy law expertise continues to increase, as courts and lawmakers wrestle with the issue of what sorts of information are protected under the law, how violations are or should be enforced, what forms of recourse and relief are available to aggrieved parties, and where such relief may be obtained. The Eleventh Circuit

Punitive Damages, Deterrent Effect, and the Constitution

Judge Rebecca F. Doherty entered an amended judgment on October 27, 2014, reducing a $6 billion award of punitive damages against Takeda and a $3 billion award against Eli Lilly in Allen v. Takeda Pharmaceutical Co. Ltd. et al., Civil No. 6:12-cv-00064, a case in the Actos MDL, proceeding in the Western District of Louisiana,

Allegedly Defective Surgical Gowns and . . . Ebola?

A physician filed a proposed class action in the Eastern District of California (Hrayr Shahinian v. Kimberly-Clark Corp.,  Civil No. 2:14-cv-08390)  on October 30, 2014, alleging that  Kimberly-Clark Corp. , a  manufacturer of “Microcool”  surgical gowns, concealed that the gowns were defective.   The plaintiff argues that the gowns were marketed as providing the highest level

Stryker Rejuvenate and ABGII Hip Implant Settlement News

A long-awaited settlement was reached between Howmedica Osteonics Corp., manufacturer of the Stryker Rejuvenate and ABG II hip implants, and representatives for persons injured by these medical devices. The settlement includes encompasses claims brought in both the federal MDL pending in the District of Minnesota ( In re: Stryker Rejuvenate and ABG II Hip Implant